Reasons for Treatment Discontinuation and Adverse Event Patterns in a Two-Decade Spondyloarthritis Biologic Registry (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2306; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Discontinuation reasons were evaluated for TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol), IL-17 inhibitors (secukinumab, ixekizumab), and JAK inhibitors (tofacitinib, upadacitinib). Treatment discontinuation patterns varied substantially across biologic and targeted therapies in real-world SpA practice. Although inefficacy remained the leading cause of discontinuation, distinct therapy-specific AE profiles also contributed to treatment cessation, highlighting the importance of both effectiveness and tolerability in long-term treatment outcomes. Figure 1."
Adverse events • Ankylosing Spondylitis • Immunology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A
|
|
Gozde Sevgi Kart Bayram1; Gizem Ayan2; Busra Firlatan Yazgan2; Buğu Bulat2; Ali Aytug Kustas3; Deniz Donmez3; Sena Bulut3; Ali Akdogan3; Omer Karadag3; Sule Apras Bilgen3; Ali İhsan Ertenli4; Sedat Kiraz3; Levent Kılıc2; Umut Kalyoncu1
|